GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Financial Group in a research report issued on Friday. They presently have a GBX 1,580 ($20.65) price target on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 10.54% from the company’s previous close.

A number of other research firms also recently issued reports on GSK. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline in a research note on Tuesday, August 21st. Berenberg Bank restated a “buy” rating and issued a GBX 1,790 ($23.39) price target on shares of GlaxoSmithKline in a research note on Thursday, August 23rd. Liberum Capital downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating and raised their price target for the stock from GBX 1,630 ($21.30) to GBX 1,700 ($22.21) in a research note on Thursday, August 30th. Barclays restated an “overweight” rating on shares of GlaxoSmithKline in a research note on Friday, August 10th. Finally, Citigroup raised their price target on GlaxoSmithKline from GBX 1,400 ($18.29) to GBX 1,600 ($20.91) and gave the stock a “neutral” rating in a research note on Friday, July 13th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and ten have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of “Hold” and an average target price of GBX 1,533.55 ($20.04).

GSK stock opened at GBX 1,429.40 ($18.68) on Friday. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($16.14) and a 1 year high of GBX 1,724.50 ($22.53).

In related news, insider David Redfern sold 1,925 shares of GlaxoSmithKline stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.58), for a total transaction of £30,318.75 ($39,616.82). Also, insider Philip R. Hampton bought 2,810 shares of the stock in a transaction that occurred on Wednesday, July 25th. The shares were bought at an average price of GBX 1,557 ($20.34) per share, for a total transaction of £43,751.70 ($57,169.35). Insiders have purchased 2,835 shares of company stock worth $4,413,165 over the last quarter.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Market Capitalization and Individual Investors

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.